KHK4083
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for KHK4083, covering 2018-03-27 to 2022-06-09. Get the full timeline:
Most recent: Clinical Trial Update: Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis [Phase 2]